NantCell has signed a definitive agreement to acquire Altor BioScience for a purchase consideration of approximately $290m.
The deal includes an upfront payment of $2m payable in cash and/or NantCell common stock.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
"The deal includes an upfront payment of $2m payable in cash or NantCell common stock."
Bailian Group has acquired approximately 23.4% stake comprising 52,185,126 A shares of Shanghai No1 Pharmacy.
The acquirer is an operator of departmental stores and shopping malls in China, while the target company operates a pharmacy chain in the same country.
